MON-309 The Role Of FGFR4 (rs351855 And rs7708357) Gene Polymorphisms And Serum Levels Association With Pituitary Adenoma

Abstract Disclosure: M. Juskiene: None. M. Duseikaite: None. I. Baikstiene: None. A. Tamasauskas: None. B. Zilaitiene: None. R. Verkauskiene: None. R. Liutkeviciene: None. Purpose: To determine the association between FGFR4 (rs351855 and rs7708357) gene polymorphisms and serum levels association with pituitary adenoma (PA). Methodology: A case-control study was conducted involving 279 subjects divided into two groups: the control group (n = 199) and a group of PA (n = 80). The genotyping of FGFR4 rs351855 and rs7708357 were carried out using the real-time polymerase chain reaction method. The serum concentration of FGFR was measured using the ELISA method. Statistical analysis of the data was performed using IBM SPSS Statistics 29.0 data analysis software. Results: There were no statistically significant results after analyzing the genotypes and alleles of FGFR4 rs351855 and rs7708357 in patients with PA and control groups (all p > 0.05). After evaluating the distribution of genotypes and alleles of FGFR4 rs351855 and rs7708357 in micro/macro, invasiveness, activity and recurrence of pituitary adenoma and the control groups, the analysis revealed no statistically significant differences between the groups (p > 0.05). For FGFR4 levels: PA patients vs. control group: median (IQR): 3642.41 (1755.08) pg/mL vs. 3126.24 (1334.15) pg/mL, p = 0.121. Conclusions: While this study did not find statistically significant associations, further research with larger sample sizes, additional genetic markers, and functional studies could provide deeper insights into the role of FGFR4 in PA development. Keywords: pituitary adenoma, FGFR4 (rs351855 and rs7708357), gene polymorphisms, ELISA. Presentation: Monday, July 14, 2025